Comparison of the diagnostic value of Ga-67 and F-18 DG-PET in sarcoidosis.
ID
Source
Brief title
Condition
- Bronchial disorders (excl neoplasms)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main study parameter is the uptake of Ga-67 citrate and F-18 DG in patients
with active sarcoidosis. Ga-67 scan and F-18 DG PET will be evaluated by three
independent nuclear physicians, who are blinded for the clinical data. Since
all patients are symptomatic and histology is obtained at the time of
inclusion, these findings are used a the *gold standard* for active
sarcoidosis. Due to the absence of an internationally accepted gold standard
for sarcoidosis activity, the specificity can not be determined.
The results will be presented as sensitivity and inter observer agreement.
Secondary outcome
not applicable
Background summary
Ga-67 scan is currently an accepted diagnostic method in the evaluation of
sarcoidosis activity and/or the extend of this disease. Recently, F-18 DG PET
has come up as a potential new molecular imaging technique in sarcoidosis.
Marked discrepancies in favour of F-18 DG PET images have been observed in some
of our patients who underwent both Ga-67 and F-18 DG PET. Some patients with
active pulmonary disease showed almost no uptake on the Ga-67 scan but fairly
positive lesions on F-18 DG PET. Furthermore, F-18 DG PET demonstrated
extra-pulmonary sarcoidosis lesions which were not visible on Ga-67 scan. This
led to the hypothesis that F-18 DG-PET imaging might be the superior nuclear
imaging technique in the assessment of sarcoidosis activity and extend, which
might have consequences with regard to treatment planning.
Study objective
Comparison of the diagnostic value of Ga-67 and F-18 DG-PET in sarcoidosis.
Study design
The study is designed as an observational cohort study.
Study burden and risks
Participation will entail one extra visit at the hospital and a small increase
of total body dose due to radiation.
However, the diagnostic value of F-18 DG PET is considered very high and dose
reduction in future patients is substantial, so we think this will justify our
research.
Koekoekslaan 1
3435 CM Nieuwegein
Nederland
Koekoekslaan 1
3435 CM Nieuwegein
Nederland
Listed location countries
Age
Inclusion criteria
Active sarcoidosis
Exclusion criteria
Pregnancy
Younger than 18 years old
Immunosuppressive therapy
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL13270.100.06 |